Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.47 |
| ▸ | FABP2 | P12104 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679174 | 0.86 | APP (0.53) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL29415828 | 0.86 | PTGS2 (0.41) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL1500630 | 0.86 | PTGS2 (0.41) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL27501994 | 0.83 | AKR1C3 (0.51) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL10443320 | 0.83 | CES2 (0.42) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL2183822 | 0.79 | PTGS1 (0.59) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL8136359 | 0.79 | PTGS1 (0.59) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL8136361 | 0.79 | PTGS1 (0.59) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL22088584 | 0.78 | CES2 (0.42) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 | |
| SCHEMBL298241 | 0.78 | AKR1C3 (0.53) | PTGS2PTGS1AKR1C3AKR1C2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0553107-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARMACEUTICALS, INC. (US) | 1993-08-04 | — | — | EP | claimed |
| WO-2025074305-A1 | N-(1-(AMINOMETHYL)CYCLOPROPYL)(ARYL OR HETEROARYL) CARBOXAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-10 | — | — | WO | disclosed |
| CN-118666764-A | Triazole amide compound, preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023141852-A1 | CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF | 益方生物科技(上海)股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4126888-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV Healthcare Company (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021194828-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| CN-106103439-B | 2,7- diaza spiro [3.5] nonane compound | 瑞敏德股份有限公司 | 2019-03-08 | — | — | CN | disclosed |
| EP-3119782-B1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2018-01-31 | — | — | EP | disclosed |
| US-9750745-B2 | 2,7-diazaspiro[3.5]nonane compounds | REMYND NV (BE) | 2017-09-05 | — | — | US | disclosed |
| WO-2007064566-A2 | HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2007-05-31 | — | — | US | disclosed |
| US-20060293299-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2006-12-28 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| EP-1636181-A1 | SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2005000809-A1 | SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI (FR) | 2004-09-02 | — | — | US | disclosed |
| EP-0553107-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARMACEUTICALS, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0386243-A1 | PLATINUM (II) COMPLEXES | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | PTGS2 3523/4885PTGS1 1253/4885AKR1C3 809/4885 |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | CNR1, CNR2, FAAH | PTGS2 2146/4885PTGS1 1400/4885AKR1C3 2172/4885 |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | PTGS2 1853/4885PTGS1 1294/4885AKR1C3 324/4885 |
| US-20040171643-A1 | Acylaminothiazole derivatives, their preparation and therapeutic use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, CBR1 | PTGS2 3119/4885PTGS1 1525/4885AKR1C3 14/4885 |
| US-20060293299-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | CNR1, CNR2, MAG | PTGS2 2061/4885PTGS1 1293/4885AKR1C3 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.